WIA
LKFT

Wealthedge Investment Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Wealthedge Investment Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,301
Closed -$311K – 193
2024
Q4 		$311K Buy
+11,301
New +$315K 0.14% 120

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Wealthedge Investment Advisors's LKFT Position: Q1 2025 in Review

Wealthedge Investment Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2025, closing a stake of 11,301 shares — an estimated $311K sold.

Wealthedge Investment Advisors first reported a position in LKFT in Q4 2024 and held it in 1 quarter. The position peaked at $311K in Q4 2024. 83 funds tracked by Wall St. Rank hold LKFT as of Q1 2025.

  • Wealthedge Investment Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2025 after selling out during the quarter.
  • Wealthedge Investment Advisors sold 11,301 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2025, an estimated $311K.
  • Wealthedge Investment Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2024 and held it in 1 quarter.
  • Wealthedge Investment Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $311K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2025.

Based on Wealthedge Investment Advisors's 13F filing for Q1 2025, filed 13 May 2025.